Constellation Pharmaceuticals Inc.

33.99+0.0200+0.06%Vol 1.31M1Y Perf 19.01%
Jul 15th, 2021 20:00 DELAYED
BID0.0000 ASK0.0000
Open33.98 Previous Close33.97
Pre-Market- After-Market-
 - -%  - -
Target Price
43.50 
Analyst Rating
Strong Buy 1.33
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Sell
Market Cap1.63B 
Earnings Date
4th Aug 2021
Alpha0.07 Standard Deviation0.51
Beta2.58 

Today's Price Range

33.9734.05

52W Range

17.0039.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-
1 Month
0.00%
3 Months
0.68%
6 Months
32.15%
1 Year
19.01%
3 Years
313.50%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CNST33.990.02000.06
AAPL146.690.84000.58
GOOG2 838.8720.10000.71
MSFT299.851.27000.43
XOM57.011.80003.26
WFC48.010.93001.98
JNJ165.611.68001.02
FB346.293.08000.90
GE103.555.01005.08
JPM161.285.37003.44
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.80-0.84-5.00
Q04 2020-0.74-0.79-6.76
Q03 2020-0.71-0.710.00
Q02 2020-0.64-0.70-9.38
Q01 2020-0.64-0.614.69
Q04 2019-0.67-0.69-2.99
Q03 2019-0.81-0.82-1.23
Q02 2019-0.80-0.800.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.89-3.49Negative
9/2021 QR-0.93-3.33Negative
12/2021 FY-3.55-6.93Negative
12/2022 FY-3.68-3.66Negative
Next Report Date-
Estimated EPS Next Report-0.89
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.31M
Shares Outstanding47.92M
Shares Float36.00M
Trades Count0
Dollar Volume31.44M
Avg. Volume940.33K
Avg. Weekly Volume837.18K
Avg. Monthly Volume964.62K
Avg. Quarterly Volume1.47M

Constellation Pharmaceuticals Inc. (NASDAQ: CNST) stock closed at 33.99 per share at the end of the most recent trading day (a 0.06% change compared to the prior day closing price) with a volume of 1.31M shares and market capitalization of 1.63B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Constellation Pharmaceuticals Inc. CEO is Jigar Raythatha.

The one-year performance of Constellation Pharmaceuticals Inc. stock is 19.01%, while year-to-date (YTD) performance is 18.02%. CNST stock has a five-year performance of %. Its 52-week range is between 17 and 39.3, which gives CNST stock a 52-week price range ratio of %

Constellation Pharmaceuticals Inc. currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 4.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.35%, a ROC of -38.21% and a ROE of -40.70%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Constellation Pharmaceuticals Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Constellation Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Constellation Pharmaceuticals Inc. is Strong Buy (1.33), with a target price of $43.5, which is 0.00% compared to the current price. The earnings rating for Constellation Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Constellation Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Constellation Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.13, ATR14 : 0.13, CCI20 : 35.09, Chaikin Money Flow : -0.50, MACD : 0.25, Money Flow Index : 0.00, ROC : 0.00, RSI : 80.71, STOCH (14,3) : 25.00, STOCH RSI : 1.00, UO : 25.40, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Constellation Pharmaceuticals Inc. in the last 12-months were: Emma Reeve (Option Excercise at a value of $133 687), Emma Reeve (Sold 17 500 shares of value $644 137 ), Karen Valentine (Option Excercise at a value of $197 835), Karen Valentine (Sold 17 203 shares of value $584 463 ), Mark A. Goldsmith (Sold 4 020 shares of value $140 769 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

Constellation Pharmaceuticals Inc.

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

CEO: Jigar Raythatha

Telephone: +1 617 714-0555

Address: 215 First Street, Cambridge 02142, MA, US

Number of employees: 154

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

53%47%

Bearish Bullish

61%39%

News

Stocktwits